00:01
We’ve heard about many different cytokines
and it is very clear that they are crucially
important in playing many, many different
roles in controlling immune responses.
00:11
But they are potentially very dangerous molecules
if they are produced in excessive quantities.
00:17
And this can happen in pathological situations where the
cytokines are produced inappropriately and can cause pathology.
00:26
There is therefore a need to develop therapeutic
agents that can block the activity of cytokines.
00:34
And one way of doing that is to
produce monoclonal antibodies.
00:39
These antibodies could be directed against the
cytokine themselves, or alternatively, they could
be directed against cytokine receptors, and
prevent binding of the cytokine to the receptor.
00:52
Of course such antibodies
should not trigger the receptor.
00:56
So we need to make sure that such antibodies don’t mimic
the effect of cytokine in triggering the receptor.
01:02
But one can produce such antibodies
that essentially get in the way of the
cytokine binding to the receptor, but
do not themselves trigger the receptor.
01:12
And here’s an example of a number of agents
that are used therapeutically in the clinic.
01:19
Some of these are antibodies against cytokines,
others are antibodies against cytokine receptors.
01:26
I won’t read through this, you can
read it perfectly well yourself.
01:29
I’ll just pick out one
of these as an example.
01:32
If you look in the middle
there you can see anti-TNFα.
01:35
And this is an agent that is used actually in a number
of different conditions - rheumatoid arthritis, plaque
psoriasis, Crohn disease, ulcerative colitis, ankylosing
spondylitis, and so forth.
01:49
In all of these conditions, there is excessive
production of TNFα that is contributing to the pathology.
01:56
So these agents, at least in a subset of patients in each
of these groups, can be very beneficial in treatment.
02:08
Conversely, sometimes in a pathological
situation, there may be either underproduction
of a cytokine or it may be that one can
beneficially stimulate responses using cytokines.
02:21
So as well as the situation where you may want
to block cytokine activity, there are other
pathological situations and disease situations
where you can use cytokines as therapeutic agents.
02:35
And again, I’m not going to
read through this whole list.
02:38
But interferons clearly have anti-viral activity,
so can be of potential use in infection.
02:47
Interleukin-2 is an immunostimulatory cytokine, so you
can use that to stimulate immune responses and so forth.